Cost-Utility of Phosphate Binders in CKD

Chaiyakittisopon and colleagues, in 2021, published a significant article consisting of a systematic review and meta-analysis titled “Evaluation of the cost-utility of phosphate binders as a treatment option for hyperphosphatemia in chronic kidney disease patients: a systematic review and meta-analysis of the economic evaluations” in “The European Journal of Health Economics.” Uncontrolled hyperphosphatemia in chronic kidney disease (CKD) patients is linked with vascular calcification and heightened risk of cardiovascular disease. Phosphate binders (PBs), including calcium-based (CBPBs) and non-calcium-based (NCBPBs) options, are commonly employed for hyperphosphatemia treatment. This study utilizes meta-analysis to assess the cost-utility of PBs in CKD patients with hyperphosphatemia.
lass=”yoast-text-mark” Relevant studies published prior to June 2019 were gathered from PubMed, Scopus, the Cochrane Library, the National Health Service Economic Evaluation Database, and the Cost-Effectiveness Analysis Registry. Inclusion criteria comprised studies involving CKD patients with hyperphosphatemia, comparing various PBs, and reporting economic outcomes

Cost-Utility of Phosphate Binders in CKD

The analysis encompassed 25 studies with 32 comparisons. Lanthanum carbonate an NCBPB emerged as a more cost-effective option than CBPBs in high-income countries (HICs). As a second-line option for pre-dialysis patients, the pooled INB was $3984.4 (599.5–7369.4). As a second-line option, the INBs were $4860.2 (641.5–9078.8) and $4011.0 (533.7–7488.3) for upper middle-income countries. Sevelamer, another NCBPB, was not more cost-effective as a first-line option compared to CBPBs, with pooled INBs of $6045.8 (−23,453.0 to 35,522.6) and $34,168.9 (−638.0 to 68,975.7) in HICs and upper-middle-income countries, respectively.

Lanthanum carbonate exhibited significant cost-effectiveness as a second-line option for hyperphosphatemia in pre-dialysis patients in HICs. However, sevelamer was not found to be more cost-effective as a first-line option than CBPBs De Oliveira and colleagues conducted an integrative literature review, and the results of this research were published in 2020 in an article titled “Vitamin K Role in Mineral and Bone Disorder of Chronic Kidney Disease.” This article was also be published in Clinica Chimica Acta in 2020. Examining the effects of vitamin K shortage and supplementation on CKD-associated mineral and bone diseases (CKD-MBD). The review digs into the body of scientific research already in existence.APA